Suchergebnisse - "Poly(ADP-ribose) Polymerase Inhibitors"

Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.

Autoren: Nakagawa A Tamauchi S Xinyuan W et al.

Quelle: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2025 Dec 15; Vol. 792, pp. 152979. Date of Electronic Publication: 2025 Nov 14.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Teratoma*/drug therapy , Teratoma*/genetics , Teratoma*/pathology , Loss of Heterozygosity* , Cell Transformation, Neoplastic*/drug effects , Cell Transformation, Neoplastic*/genetics, Xenograft Model Antitumor Assays ; Humans ; Animals ; Mice ; Female ; Mice, Inbred BALB C ; Aged ; Mutation ; AMP-Activated Protein Kinase Kinases/genetics ; Genomic Instability/drug effects ; Gene Expression Profiling ; Genomics

SCR Disease Name: Teratoma, Ovarian

Optimization of 2,3-dihydrophthalazine-1,4-dione PARP inhibitor scaffold for nanomolar potency and specificity towards human PARP10.

Autoren: Alaviuhkola J Nizi MG Vagaggini C et al.

Quelle: European journal of medicinal chemistry [Eur J Med Chem] 2025 Dec 15; Vol. 300, pp. 118111. Date of Electronic Publication: 2025 Sep 01.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/chemical synthesis , Phthalazines*/chemistry , Phthalazines*/pharmacology , Phthalazines*/chemical synthesis , Poly(ADP-ribose) Polymerases*/metabolism, Humans ; Structure-Activity Relationship ; Molecular Structure ; Dose-Response Relationship, Drug ; Apoptosis/drug effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/chemical synthesis ; Cell Proliferation/drug effects ; Proto-Oncogene Proteins

Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance.

Autoren: Sun Z Hu M Xu J et al.

Quelle: European journal of medicinal chemistry [Eur J Med Chem] 2025 Dec 15; Vol. 300, pp. 118164. Date of Electronic Publication: 2025 Sep 14.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Proto-Oncogene Proteins c-met*/antagonists & inhibitors , Proto-Oncogene Proteins c-met*/metabolism , Benzofurans*/chemistry , Benzofurans*/pharmacology , Benzofurans*/chemical synthesis , Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Poly (ADP-Ribose) Polymerase-1*/metabolism , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/chemical synthesis , Drug Resistance, Neoplasm*/drug effects , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Drug Discovery* , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/chemical synthesis, Humans ; Structure-Activity Relationship ; Animals ; Molecular Structure ; Mice ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Dose-Response Relationship, Drug

Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study.

Autoren: Takatori E Shoji T Jo A et al.

Quelle: Anticancer research [Anticancer Res] 2025 Dec; Vol. 45 (12), pp. 5773-5783.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

MeSH-Schlagworte: Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/mortality , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Neoplasm Recurrence, Local*/drug therapy , Neoplasm Recurrence, Local*/pathology, Humans ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Adult ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Treatment Outcome ; Organoplatinum Compounds/administration & dosage ; Doxorubicin/administration & dosage ; Platinum/therapeutic use

Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development.

Autoren: Li LT Zhang SC Yang YY et al.

Quelle: Bioorganic chemistry [Bioorg Chem] 2025 Dec; Vol. 167, pp. 109244. Date of Electronic Publication: 2025 Nov 15.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE

MeSH-Schlagworte: Poly (ADP-Ribose) Polymerase-1*/metabolism , Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Neoplasms*/drug therapy , Neoplasms*/metabolism , Neoplasms*/pathology , Protein Serine-Threonine Kinases*/metabolism , Protein Serine-Threonine Kinases*/antagonists & inhibitors , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemistry, Humans ; Molecular Structure ; Animals

Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability.

Autoren: Attwa MW Abdelhameed AS AlRabiah H et al.

Quelle: The Analyst [Analyst] 2025 Dec 01; Vol. 150 (24), pp. 5501-5513. Date of Electronic Publication: 2025 Dec 01.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 0372652 Publication Model: Electronic Cited Medium: Internet ISSN: 1364-5528 (Electronic) Linking ISSN: 00032654 NLM ISO Abbreviation: Analyst Subsets: MEDLINE

MeSH-Schlagworte: Tandem Mass Spectrometry*/methods , Microsomes, Liver*/metabolism , Benzimidazoles*/metabolism , Benzimidazoles*/analysis , Benzimidazoles*/pharmacokinetics , Benzimidazoles*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/metabolism , Poly(ADP-ribose) Polymerase Inhibitors*/analysis, Humans ; Chromatography, High Pressure Liquid/methods ; Hydrophobic and Hydrophilic Interactions ; Computer Simulation ; Drug Stability ; Liquid Chromatography-Mass Spectrometry

Structure-based design of new potent and highly selective PARP-1 inhibitor for treating colorectal cancer.

Autoren: Jiang C Yang S Wang Y et al.

Quelle: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2025 Dec; Vol. 40 (1), pp. 2542358. Date of Electronic Publication: 2025 Aug 12.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Poly (ADP-Ribose) Polymerase-1*/metabolism , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/metabolism , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/chemical synthesis , Drug Design* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis, Humans ; Structure-Activity Relationship ; Cell Proliferation/drug effects ; Molecular Structure ; Drug Screening Assays, Antitumor ; Dose-Response Relationship, Drug ; Cell Line, Tumor

Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when treating cervical cancer in an in vivo mouse model.

Autoren: IJff M Mei X Scutigliani EM et al.

Quelle: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group [Int J Hyperthermia] 2025 Dec; Vol. 42 (1), pp. 2450514. Date of Electronic Publication: 2025 Jan 21.

Publikationsart: Journal Article; Research Support, Non-U.S. Gov't

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8508395 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-5157 (Electronic) Linking ISSN: 02656736 NLM ISO Abbreviation: Int J Hyperthermia Subsets: MEDLINE

MeSH-Schlagworte: Uterine Cervical Neoplasms*/therapy , Uterine Cervical Neoplasms*/drug therapy , Uterine Cervical Neoplasms*/pathology , Chemoradiotherapy*/methods , Hyperthermia, Induced*/methods , Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology, Animals ; Female ; Humans ; Mice ; Mice, Nude ; Cisplatin/therapeutic use ; Cisplatin/pharmacology ; Phthalazines/pharmacology ; Phthalazines/therapeutic use ; Cell Line, Tumor ; HeLa Cells ; Piperazines

[Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice].

Transliterierter Titel: Therapiemanagement des mCRPC bei Kombinationen mit PARP-Inhibitoren in der klinischen Praxis.

Autoren: Retz M Borkowetz A Wittenzellner K et al.

Quelle: Aktuelle Urologie [Aktuelle Urol] 2025 Dec; Vol. 56 (6), pp. 552-568. Date of Electronic Publication: 2025 Oct 27.

Publikationsart: Journal Article; Review; English Abstract

Info zur Zeitschrift: Publisher: Thieme Country of Publication: Germany NLM ID: 0421406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1438-8820 (Electronic) Linking ISSN: 00017868 NLM ISO Abbreviation: Aktuelle Urol Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/pathology , Androgen Receptor Antagonists*/therapeutic use , Androgen Receptor Antagonists*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male

Evaluation of Niraparib Metabolic Stability in Human Liver Microsomes Using Ultrafast UPLC-MS/MS Technique: In Silico Screening for Structural Alerts Related to the Metabolic Lability and In Silico DEREK Toxicity.

Autoren: Attwa MW Abdelhameed AS Kadi AA

Quelle: Biomedical chromatography : BMC [Biomed Chromatogr] 2025 Dec; Vol. 39 (12), pp. e70252.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Country of Publication: England NLM ID: 8610241 Publication Model: Print Cited Medium: Internet ISSN: 1099-0801 (Electronic) Linking ISSN: 02693879 NLM ISO Abbreviation: Biomed Chromatogr Subsets: MEDLINE

MeSH-Schlagworte: Tandem Mass Spectrometry*/methods , Microsomes, Liver*/metabolism , Indazoles*/metabolism , Indazoles*/chemistry , Indazoles*/analysis , Indazoles*/toxicity , Indazoles*/pharmacokinetics , Piperidines*/metabolism , Piperidines*/chemistry , Piperidines*/analysis , Piperidines*/pharmacokinetics , Piperidines*/toxicity , Poly(ADP-ribose) Polymerase Inhibitors*/metabolism , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/analysis, Humans ; Chromatography, High Pressure Liquid/methods ; Reproducibility of Results ; Linear Models ; Drug Stability ; Computer Simulation ; Limit of Detection ; Liquid Chromatography-Mass Spectrometry

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Autoren: Kozarich AM Katti RU Mensah GAK et al.

Quelle: Biochemical pharmacology [Biochem Pharmacol] 2025 Dec; Vol. 242 (Pt 4), pp. 117414. Date of Electronic Publication: 2025 Oct 10.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/metabolism , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Antineoplastic Agents*/metabolism , Antineoplastic Agents*/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1*/metabolism, Humans ; Phthalazines/pharmacology ; Phthalazines/metabolism ; Piperazines/pharmacology ; Piperazines/metabolism ; Indazoles/pharmacology ; Indazoles/metabolism ; Indoles/pharmacology ; Indoles/metabolism ; Piperidines/pharmacology ; Piperidines/metabolism ; Biological Transport/physiology ; Biological Transport/drug effects

Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System.

Autoren: Ogura T Shiraishi C

Quelle: Expert opinion on drug safety [Expert Opin Drug Saf] 2025 Dec; Vol. 24 (12), pp. 1443-1451. Date of Electronic Publication: 2024 Oct 23.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology, Humans ; United States ; Female ; United States Food and Drug Administration ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Middle Aged ; Aged ; Indazoles/adverse effects ; Indazoles/administration & dosage ; Piperidines/adverse effects ; Piperidines/administration & dosage ; Phthalazines/adverse effects ; Phthalazines/administration & dosage ; Adult ; Piperazines/adverse effects ; Piperazines/administration & dosage ; Indoles/adverse effects ; Indoles/administration & dosage ; Pyrazoles/adverse effects ; Pyrazoles/administration & dosage ; Aged, 80 and over

Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy.

Autoren: Apostol AI Bruno M Sassu CM et al.

Quelle: International journal of clinical oncology [Int J Clin Oncol] 2025 Dec; Vol. 30 (12), pp. 2652-2661. Date of Electronic Publication: 2025 Nov 04.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

MeSH-Schlagworte: Piperidines*/adverse effects , Piperidines*/therapeutic use , Piperidines*/administration & dosage , Indazoles*/adverse effects , Indazoles*/therapeutic use , Indazoles*/administration & dosage , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use, Humans ; Female ; Aged ; Middle Aged ; Retrospective Studies ; Progression-Free Survival ; Age Factors

Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review.

Autoren: Wahba L Nabil S Kendakji S et al.

Quelle: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2440631. Date of Electronic Publication: 2024 Dec 13.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH-Schlagworte: Phthalazines*/adverse effects , Phthalazines*/therapeutic use , Piperazines*/adverse effects , Piperazines*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use, Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Aged ; Adult ; Anemia/chemically induced ; Anemia/epidemiology ; United Arab Emirates/epidemiology ; Thrombocytopenia/chemically induced ; Thrombocytopenia/epidemiology ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Treatment Outcome

Roles and therapeutic potential of PARP-1 in neurodegenerative diseases.

Autoren: Liu C Lai FF Zhang T et al.

Quelle: Biochemical pharmacology [Biochem Pharmacol] 2025 Dec; Vol. 242 (Pt 3), pp. 117373. Date of Electronic Publication: 2025 Sep 27.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Neurodegenerative Diseases*/drug therapy , Neurodegenerative Diseases*/enzymology , Neurodegenerative Diseases*/metabolism , Poly (ADP-Ribose) Polymerase-1*/metabolism , Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology, Humans ; Animals ; DNA Damage/drug effects ; DNA Damage/physiology

Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura.

Autoren: Lu P Wang D Bao X et al.

Quelle: Journal of ovarian research [J Ovarian Res] 2025 Nov 26; Vol. 18 (1), pp. 286. Date of Electronic Publication: 2025 Nov 26.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Ovarian Epithelial*/drug therapy , Carcinoma, Ovarian Epithelial*/genetics , Carcinoma, Ovarian Epithelial*/complications , Carcinoma, Ovarian Epithelial*/pathology , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/complications , Ovarian Neoplasms*/pathology , Purpura, Thrombocytopenic, Idiopathic*/complications , Purpura, Thrombocytopenic, Idiopathic*/drug therapy , BRCA1 Protein*/genetics, Humans ; Female ; Middle Aged ; Mutation ; Remission Induction ; Neoplasm Staging ; Phthalazines/therapeutic use ; Phthalazines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Piperazines

The golden touch: a comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors.

Autoren: Khanehzar E Shams F Jafari A

Quelle: Medical oncology (Northwood, London, England) [Med Oncol] 2025 Nov 24; Vol. 43 (1), pp. 20. Date of Electronic Publication: 2025 Nov 24.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

MeSH-Schlagworte: Curcumin*/pharmacology , Curcumin*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Neoplasms*/drug therapy , Network Pharmacology*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology, Humans ; Drug Synergism ; Animals ; DNA Repair/drug effects ; Signal Transduction/drug effects

RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors.

Autoren: Chandramouly G Fried W Gordon J et al.

Quelle: Journal of medicinal chemistry [J Med Chem] 2025 Nov 13; Vol. 68 (21), pp. 22196-22215. Date of Electronic Publication: 2025 Oct 22.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , DNA-Directed DNA Polymerase*/metabolism , DNA-Directed DNA Polymerase*/chemistry , BRCA2 Protein*/genetics , BRCA1 Protein*/genetics , Enzyme Inhibitors*/pharmacology , Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/administration & dosage , Enzyme Inhibitors*/pharmacokinetics , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/pharmacokinetics , Antineoplastic Agents*/administration & dosage, Humans ; Animals ; Administration, Oral ; Female ; Mice ; DNA Polymerase theta ; Biological Availability ; Cell Line, Tumor ; Structure-Activity Relationship ; Mutation ; Xenograft Model Antitumor Assays ; Rats ; Crystallography, X-Ray

Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study.

Autoren: Lian X Lei Y

Quelle: JMIR medical informatics [JMIR Med Inform] 2025 Nov 12; Vol. 13, pp. e72994. Date of Electronic Publication: 2025 Nov 12.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101645109 Publication Model: Electronic Cited Medium: Internet ISSN: 2291-9694 (Electronic) Linking ISSN: 22919694 NLM ISO Abbreviation: JMIR Med Inform Subsets: MEDLINE

MeSH-Schlagworte: Ovarian Neoplasms*/drug therapy , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Hematologic Diseases*/chemically induced, Humans ; Female ; Prospective Studies ; Middle Aged ; Aged ; Risk Factors ; Adult ; Risk Assessment/methods

Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives.

Autoren: Ye GW Zhang YQ He ML et al.

Quelle: European journal of medicinal chemistry [Eur J Med Chem] 2025 Nov 05; Vol. 297, pp. 117937. Date of Electronic Publication: 2025 Jul 05.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/chemistry , Poly (ADP-Ribose) Polymerase-1*/antagonists & inhibitors , Poly (ADP-Ribose) Polymerase-1*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Neoplasms*/drug therapy , Neoplasms*/metabolism , Neoplasms*/pathology, Humans ; Synthetic Lethal Mutations/drug effects ; Structure-Activity Relationship ; Molecular Structure ; Animals